A Phase 2 interventional study of NIS793 and Bevacizumab in Metastatic Colorectal Cancer, sponsored by Novartis Pharmaceuticals. Terminated at 55 sites in 17 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Colorectal Neoplasms by Novartis — 3 open to participants now, 7 under way, none of them phase 3. Colorectal Neoplasms · Novartis.
Among the 30 studies in Colorectal Neoplasms by Novartis, this one is the 6th largest by enrollment, is one of 2 that started in 2021, is one of 4 in phase 2, and was the 23rd registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →3 of the 30 studies in Colorectal Neoplasms by Novartis are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Denmark, Japan
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Canada, Denmark and 4 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Belgium, Canada and 7 more countries
Ages 18–100
By country, each count listing its studies:
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 8 · Phase 3 4 · Phase 4 1
First in 1999; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 202 is above the median of 76 across 4,811 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 123 across the 30 interventional studies. Of the 23 that completed or were terminated, 5 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,723 studies on the registry; 222 are open to participants now.
Of its 587 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
3 of the studies in Colorectal Neoplasms by Novartis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04699188Novartis PharmaceuticalsStudy of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | 2027-01-25 |
| NCT05838768Novartis PharmaceuticalsStudy of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency. | 2027-08-31 |
| NCT05544929Novartis PharmaceuticalsA Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | 2027-10-05 |
Add all 3 to your calendar (.ics) → With an account.
Among the 30 studies in Colorectal Neoplasms by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate the preliminary efficacy and safety of NIS793 and other novel investigational combinations with standard of care (SOC) anti-cancer therapy versus SOC anti-cancer therapy for the second-line treatment of mCRC.
This study aimed to explore whether different mechanisms of action could reverse resistance and improve responsiveness to the then-considered SOC anti-cancer therapy in the second-line metastatic colorectal cancer (mCRC) setting.
This was an open-label, multi-center, Phase II platform study with both control and investigational arms. Each investigational arm included a Safety Run-In (SRI) phase, followed by an Expansion Part. In the control arm, the standard of care (SoC) anti-cancer therapy consisted of bevacizumab in combination with either modified FOLFOX6 (mFOLFOX6: folinic acid, fluorouracil, and oxaliplatin) or FOLFIRI (folinic acid, fluorouracil, and irinotecan).
On July 31, 2023, administration of NIS793 and tislelizumab was halted, and this action was subsequently classified as an Urgent Safety Measure on August 3, 2023, due to an unfavorable benefit/risk profile observed in participants with metastatic colorectal cancer (mCRC).
Each investigational arm included a combination of an investigational drug and the standard of care anti-cancer therapy:
Safety Run-In Part:
The Safety Run-In (SRI) phase was initiated to confirm the recommended phase 2 dose (RP2D) of the investigational drug(s) in combination with standard of care anti-cancer therapy.
For Investigational arm #1, the SRI for both FOLFIRI and mFOLFOX6 regimens was fully enrolled. The RP2D for SRI arm #1 (both FOLFIRI and mFOLFOX6) was declared, and the Expansion Part for arm #1 (both FOLFIRI and mFOLFOX6) was opened and fully enrolled.
\~ Duration: Each SRI part enrolled up to approximately 20 participants per regimen, with the SRI phase typically lasting until at least 12 evaluable participants completed one 28-day treatment cycle (4 weeks) per regimen.
Expansion Part:
The decision to open the Expansion Part of the study was based on dose confirmation of the investigational drug, with available safety, relevant pharmacokinetic (PK), and other relevant clinical and laboratory data from the SRI phase. The Expansion Part ran independently for each standard of care anti-cancer therapy (mFOLFOX6 or FOLFIRI with bevacizumab).
\~ Duration: Each Expansion Part was planned to enroll approximately 75 participants per investigational arm and per regimen, with treatment cycles of 28 days each. Participants continued in the Expansion Part until unacceptable toxicity, disease progression, withdrawal of consent, or other protocol-specified discontinuation criteria were met.
After NIS793 and tislelizumab were permanently discontinued, participants were allowed to continue with standard of care therapy as assessed by the Investigator. No additional treatment arms were introduced during the study.
The criteria were revised on the registry on Nov 16, 2026. See what changed
Key Inclusion criteria:
Key Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FOLFOX6 or FOLFIRI) and NIS793 to confirm the RP2D of NIS793
Drug: NIS793 · Drug: Bevacizumab · Drug: Modified FOLFOX6 · Drug: FOLFIRI
Participants were treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FOLFOX6 or FOLFIRI) and NIS793 at the RP2D defined in the safety run-in
Drug: NIS793 · Drug: Bevacizumab · Drug: Modified FOLFOX6 · Drug: FOLFIRI
Participants were treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FOLFOX6 or FOLFIRI)
Drug: Bevacizumab · Drug: Modified FOLFOX6 · Drug: FOLFIRI
Participants were treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FOLFOX6 or FOLFIRI), NIS793, and tislelizumab to confirm the RP2D of NIS793
Drug: NIS793 · Drug: Bevacizumab · Drug: Modified FOLFOX6 · Drug: FOLFIRI · Drug: Tislelizumab
Participants were treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FOLFOX6 or FOLFIRI), NIS793, and tislelizumab at the RP2D for NIS793 defined in the safety run-in
Drug: NIS793 · Drug: Bevacizumab · Drug: Modified FOLFOX6 · Drug: FOLFIRI · Drug: Tislelizumab
Investigational drug NIS793 was administered intravenously (IV) at the dose and schedule determined in the safety run-in part
Bevacizumab was administered intravenously (IV)
5-fluorouracil \[administered as a continuous infusion\], leucovorin \[administered IV\] (or levoleucovorin \[administered IV\]), and oxaliplatin \[administered IV\]
Also known as: 5FU+Leucovorin+Oxaliplatin
5-fluorouracil \[administered as a continuous infusion\], leucovorin \[administered IV\] (or levoleucovorin \[administered IV\]), and irinotecan \[administered IV\]
Also known as: 5FU+Leucovorin+Irinotecan
Investigational drug tislelizumab was administered intravenously (IV)
Also known as: VDT482
(Safety run-in Part) Number of Participants With Dose Limiting Toxicities (DLTs) During the First Cycle (4 Weeks) of Treatment.
The primary endpoint for the Safety Run-In part was the incidence of dose-limiting toxicities (DLT) during the first 28 days of treatment with investigational drug(s) (NIS793 with or without tislelizumab) and standard of care anti-cancer therapy. Dose tolerability decisions were based on all safety data and a Bayesian Logistic Regression Model (BLRM) using Escalation with Overdose Control (EWOC) criteria. Dose confirmation required at least six evaluable participants, fulfillment of EWOC criteria, and recommendation by Novartis and investigators after reviewing clinical, pharmacokinetic, and laboratory data.
Time frame: Up to 4 weeks
(Expansion Part) Progression-free Survival (PFS) by Investigator Assessment Per RECIST 1.1
PFS was defined as the time from the date of enrollment (run-in part) or randomization (randomized part) to the date of the first documented progression based on investigator assessment and according to RECIST 1.1 or death due to any cause
Time frame: From randomization up to disease progression or death, assessed up to approximately 11 months
(Safety run-in Part) Percentage of Participants With Adverse Events (AEs)
Percentage of participants who experienced AEs and SAEs, including changes in laboratory parameters, vital signs, body weight, and cardiac assessments
Time frame: Through Safety Run-in completion, an average of 6 months
(Safety Run-In) Percentage of Participants With Dose Interruptions and Dose Reductions of Investigational Drug
Tolerability was measured by the percentage of subjects who had dose adjustments (interruptions or reductions) of investigational drug (NIS793, NIS793 + tislelizumab)
Time frame: Up to approximately 7 months
(Safety Run-In) Dose Intensity of Investigational Drug
Tolerability was measured by the dose intensity of the investigational drug (e.g., NIS793, NIS793 + tislelizumab). Dose intensity was computed as the ratio of the actual cumulative dose received to the actual duration of exposure.
Time frame: Up to approximately 7 months
(Safety run-in Part) PFS by Investigator Assessment Per RECIST 1.1
PFS was defined as the time from the date of enrollment to the date of the first documented progression based on investigator assessment and according to RECIST 1.1 or death due to any cause
Time frame: From enrollment up to disease progression or death, assessed up to approximately 7 months
(Safety run-in Part) Overall Response Rate (ORR) by Investigator Assessment Per RECIST 1.1
ORR was defined as the proportion of participants with a best overall response (BOR) of complete response (CR) or partial response (PR), as per investigator assessment and according to RECIST 1.1
Time frame: Up to approximately 7 months
(Safety run-in Part) Disease Control Rate (DCR) by Investigator Assessment Per RECIST 1.1
DCR was defined as the proportion of participants with a best overall response (BOR) of complete response (CR), partial response (PR), or stable disease (SD), as per investigator assessment and according to RECIST 1.1
Time frame: Up to approximately 7 months
(Safety run-in Part) Duration of Response (DOR) by Investigator Assessment Per RECIST 1.1
DOR was defined as the duration of time between the date of the first documented response (CR or PR) and the date of first documented progression or death due to any cause
Time frame: From first documented response up to disease progression or death, assessed up to approximately 7 months
(Safety run-in Part) Time to Response (TTR) by Investigator Assessment Per RECIST 1.1
TTR was defined as the duration of time between the date of enrollment and the date of the first documented response of either CR or PR
Time frame: From enrollment up to first documented response, assessed up to approximately 7 months
(Safety run-in Part) Overall Survival (OS)
OS was defined as the time from the date of enrollment to the date of death due to any cause
Time frame: Up to two years
(Safety run-in Part) Maximum Concentration (Cmax) of NIS793 and Tislelizumab
Blood samples were collected at indicated time-points for analysis of Cmax of NIS793 and tislelizumab.
Time frame: Cycle 1 Day 1, Cycle 3 Day 1 (1 cycle = 28 days).
(Safety run-in Part) Trough Concentration (Ctrough) of NIS793 and Tislelizumab
Blood samples were collected at indicated time-points for analysis of Ctrough of NIS793 and tislelizumab
Time frame: Cycle 1 Day 15, Cycle 3 Day 1, Cycle 3 Day 15, Cycle 6 Day 1 (1 cycle = 28 days)
(Safety run-in Part) NIS793 and Tislelizumab Antidrug Antibodies (ADA) at Baseline
Prevalence of NIS793 and Tislelizumab Antidrug antibodies (ADA) at baseline was defined as the proportion of participants who had an ADA positive result at baseline
Time frame: Baseline
(Safety run-in Part) NIS793 and Tislelizumab Antidrug Antibodies (ADA) Incidence on Treatment
Incidence of NIS793 and Tislelizumab Antidrug antibodies (ADA) on treatment was defined as the proportion of participants who were treatment-induced ADA positive (post-baseline ADA positive with an ADA-negative sample at baseline) and treatment-boosted ADA positive (post-baseline ADA positive with a titer that was at least the fold titer change greater than the ADA-positive baseline titer)
Time frame: From the date of first study drug intake up to approximately 7 months
(Expansion Part) Percentage of Participants With Adverse Events (AEs)
The percentage of participants who experienced AEs and SAEs, including changes in laboratory parameters, vital signs, body weight, and cardiac assessments
Time frame: Through Expansion completion, an average of 8 months
(Expansion Part) Percentage of Participants With Dose Interruptions and Dose Reductions of Investigational Drug
Tolerability was measured by the percentage of subjects who had dose adjustments (interruptions) of the investigational drug (e.g., NIS793, NIS793 + tislelizumab)
Time frame: Up to approximately 11 months
(Expansion Part) Dose Intensity of Investigational Drug
Tolerability was measured by the dose intensity of the investigational drug (e.g., NIS793, NIS793 + Tislelizumab). Dose intensity was computed as the ratio of the actual cumulative dose received to the actual duration of exposure.
Time frame: Up to approximately 11 months
(Expansion Part) Overall Response Rate (ORR) by Investigator Assessment Per RECIST 1.1
ORR was defined as the proportion of participants with a best overall response (BOR) of complete response (CR) or partial response (PR), as per investigator assessment and according to RECIST 1.1
Time frame: Up to approximately 11 months
(Expansion Part) Disease Control Rate (DCR) by Investigator Assessment Per RECIST 1.1
DCR was defined as the proportion of participants with a best overall response (BOR) of complete response (CR), partial response (PR), or stable disease (SD), as per investigator assessment and according to RECIST 1.1
Time frame: Up to approximately 11 months
(Expansion Part) Duration of Response (DOR) by Investigator Assessment Per RECIST 1.1
DOR was defined as the duration of time between the date of the first documented response (CR or PR) and the date of first documented progression or death due to any cause
Time frame: From first documented response up to disease progression or death, assessed up to approximately 11 months
(Expansion Part) Time to Response (TTR) by Investigator Assessment Per RECIST 1.1
TTR was defined as the duration of time between the date of enrollment and the date of first documented response of either CR or PR
Time frame: From enrollment up to first documented response, assessed up to approximately 11 months
(Expansion Part) Overall Survival (OS)
OS was defined as the time from the date of enrollment to the date of death due to any cause
Time frame: Up to two years
(Expansion Part) Maximum Concentration (Cmax) of NIS793 and Tislelizumab
Blood samples were collected at indicated time-points for analysis of Cmax of NIS793 and tislelizumab
Time frame: Cycle 1 Day 1, Cycle 3 Day 1 (NIS793 only) (1 cycle = 28 days)
(Expansion Part) Trough Concentration (Ctrough) of NIS793 and Tislelizumab
Blood samples were collected at indicated time-points for analysis of Ctrough of NIS793 and tislelizumab
Time frame: Cycle 1 Day 15 (NIS793 only), Cycle 2 Day (tislelizumab only), Cycle 3 Day 1, Cycle 3 Day 15 (NIS793 only), Cycle 4 Day (tislelizumab only), Cycle 6 Day 1 (NIS793 only) (1 cycle = 28 days)
(Expansion Part) NIS793 and Tislelizumab Antidrug Antibodies (ADA) at Baseline
Prevalence of NIS793 and Tislelizumab Antidrug antibodies (ADA) at baseline was defined as the proportion of participants who had an ADA positive result at baseline
Time frame: Baseline
(Expansion Part) NIS793 and Tislelizumab Antidrug Antibodies (ADA) Incidence on Treatment
Incidence of NIS793 and Tislelizumab Antidrug antibodies (ADA) on treatment was defined as the proportion of participants who were treatment-induced ADA positive (post-baseline ADA positive with an ADA-negative sample at baseline) and treatment-boosted ADA positive (post-baseline ADA positive with a titer that was at least the fold titer change greater than the ADA-positive baseline titer)
Time frame: From the date of first study drug intake up to approximately 11 months
The study was conducted globally across 17 countries: Australia (3 centers), Belgium (3 centers), Canada (4 centers), Switzerland (1 center), Czech Republic (3 centers), Germany (8 centers), Spain (5 centers), France (3 centers), United Kingdom (3 centers), Hong Kong (2 centers), Israel (2 centers), Italy (3 centers), Japan (5 centers), Korea (1 center), Singapore (1 center), Taiwan (2 centers), and USA (7 centers).
| Milestone | Safety Run-In (Investigational Arm 1): NIS793+SoC (FOLFIRI) | Safety Run-In (Investigational Arm 1): NIS793+SoC (mFOLFOX6) | Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI) | Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (mFOLFOX6) | Expansion (Investigational Arm 1): NIS793+SoC (FOLFIRI) | Expansion (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI) | Expansion (Control Arm): SoC (FOLFIRI) | Expansion (Investigational Arm 1): NIS793+SoC (mFOLFOX6) | Expansion (Control Arm): SoC (mFOLFOX6) |
|---|---|---|---|---|---|---|---|---|---|
| Started | 13 | 9 | 10 | 8 | 67 | 29 | 46 | 13 | 7 |
| Safety set | 13 | 9 | 10 | 8 | 65 | 29 | 46 | 15 | 7 |
| Pharmacokinetic analysis sets (pas) for nis793 (nis-pas) | 13 | 9 | 4 | 2 | 60 | 18 | 0 | 12 | 0 |
| Pharmacokinetic analysis sets (pas) tislelizumab (tsl-pas) | 0 | 0 | 9 | 4 | 0 | 19 | 0 | 0 | 0 |
| Immunogenicity (ig) prevalence set for nis793 | 13 | 9 | 7 | 6 | 65 | 21 | 0 | 15 | 0 |
| Immunogenicity (ig) prevalence set for tislelizumab | 0 | 0 | 10 | 8 | 0 | 28 | 0 | 0 | 0 |
| Immunogenicity incidence set - nis793 | 10 | 8 | 2 | 0 | 55 | 5 | 0 | 12 | 0 |
| Immunogenicity incidence set - tislelizumab | 0 | 0 | 6 | 4 | 0 | 20 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 13 | 9 | 10 | 8 | 67 | 29 | 46 | 13 | 7 |
| Withdrew: Progressive disease | 10 | 6 | 9 | 5 | 46 | 15 | 26 | 10 | 5 |
| Withdrew: Physician decision | 2 | 0 | 0 | 1 | 9 | 3 | 4 | 1 | 0 |
| Withdrew: Adverse event | 1 | 1 | 1 | 1 | 4 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 2 | 0 | 1 | 4 | 4 | 7 | 2 | 2 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 0 | 3 | 6 | 7 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
The primary endpoint for the Safety Run-In part was the incidence of dose-limiting toxicities (DLT) during the first 28 days of treatment with investigational drug(s) (NIS793 with or without tislelizumab) and standard of care anti-cancer therapy. Dose tolerability decisions were based on all safety data and a Bayesian Logistic Regression Model (BLRM) using Escalation with Overdose Control (EWOC) criteria. Dose confirmation required at least six evaluable participants, fulfillment of EWOC criteria, and recommendation by Novartis and investigators after reviewing clinical, pharmacokinetic, and laboratory data.
| Participants | Safety Run-In (Investigational Arm 1): NIS793+SoC (FOLFIRI) | Safety Run-In (Investigational Arm 1): NIS793+SoC (mFOLFOX6) | Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI) | Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (mFOLFOX6) |
|---|---|---|---|---|
| (Safety run-in Part) Number of Participants With Dose Limiting Toxicities (DLTs) During the First Cycle (4 Weeks) of Treatment. | 1 | 1 | 1 | 0 |
PFS was defined as the time from the date of enrollment (run-in part) or randomization (randomized part) to the date of the first documented progression based on investigator assessment and according to RECIST 1.1 or death due to any cause
| Months | Expansion (Investigational Arm 1): NIS793+SoC | Expansion (Investigational Arm 2): NIS793+TISLE+SoC | Expansion (Control Arm): SoC |
|---|---|---|---|
| (Expansion Part) Progression-free Survival (PFS) by Investigator Assessment Per RECIST 1.1 | 5.1 (3.6 to 5.7) | 3.7 (2.2 to 5.6) | 7.4 (5.5 to 9.4) |
Percentage of participants who experienced AEs and SAEs, including changes in laboratory parameters, vital signs, body weight, and cardiac assessments
| Participants | Safety Run-In (Investigational Arm 1): NIS793+SoC (FOLFIRI) | Safety Run-In (Investigational Arm 1): NIS793+SoC (mFOLFOX6) | Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI) | Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (mFOLFOX6) |
|---|---|---|---|---|
| Adverse Events (AEs) | 13 | 9 | 10 | 8 |
| Serious Adverse Events (SAEs) | 6 | 6 | 6 | 5 |
| Fatal SAEs | 0 | 0 | 0 | 0 |
| AEs leading to discontinuation | 5 | 3 | 1 | 2 |
| AEs leading to dose adjustment/interruption | 12 | 7 | 9 | 7 |
| AEs requiring additional therapy | 13 | 9 | 10 | 8 |
Tolerability was measured by the percentage of subjects who had dose adjustments (interruptions or reductions) of investigational drug (NIS793, NIS793 + tislelizumab)
| Participants | Safety Run-In (Investigational Arm 1): NIS793+SoC (FOLFIRI) | Safety Run-In (Investigational Arm 1): NIS793+SoC (mFOLFOX6) | Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI) | Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (mFOLFOX6) |
|---|---|---|---|---|
| NIS793: Participants with at least one dose reduction | 1 | 0 | 0 | 0 |
| NIS793: Participants with at least one dose interruption | 8 | 6 | 9 | 5 |
| Tislelizumab: Participants with at least one dose reduction | 0 | 0 | 0 | 0 |
| Tislelizumab: Participants with at least one dose interruption | 0 | 0 | 5 | 2 |
Tolerability was measured by the dose intensity of the investigational drug (e.g., NIS793, NIS793 + tislelizumab). Dose intensity was computed as the ratio of the actual cumulative dose received to the actual duration of exposure.
| mg/cycle | Safety Run-In (Investigational Arm 1): NIS793+SoC (FOLFIRI) | Safety Run-In (Investigational Arm 1): NIS793+SoC (mFOLFOX6) | Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI) | Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (mFOLFOX6) |
|---|---|---|---|---|
| NIS793 | 4171.2 ± 664.81 | 3792.7 ± 426.97 | 3550.5 ± 387.83 | 3703.4 ± 627.94 |
| Tislelizumab | — | — | 273.1 ± 28.72 | 277.9 ± 45.58 |
PFS was defined as the time from the date of enrollment to the date of the first documented progression based on investigator assessment and according to RECIST 1.1 or death due to any cause
| Months | Safety Run-In (Investigational Arm 1): NIS793+SoC | Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC |
|---|---|---|
| (Safety run-in Part) PFS by Investigator Assessment Per RECIST 1.1 | 3.6 (1.9 to 7.3) | 2.1 (1.8 to 4.3) |
ORR was defined as the proportion of participants with a best overall response (BOR) of complete response (CR) or partial response (PR), as per investigator assessment and according to RECIST 1.1
| Percentage of Responders | Safety Run-In (Investigational Arm 1): NIS793+SoC | Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC |
|---|---|---|
| (Safety run-in Part) Overall Response Rate (ORR) by Investigator Assessment Per RECIST 1.1 | 4.5 (0.1 to 22.8) | 0 (NA to NA) |
DCR was defined as the proportion of participants with a best overall response (BOR) of complete response (CR), partial response (PR), or stable disease (SD), as per investigator assessment and according to RECIST 1.1
| Percentage of Responders | Safety Run-In (Investigational Arm 1): NIS793+SoC | Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC |
|---|---|---|
| (Safety run-in Part) Disease Control Rate (DCR) by Investigator Assessment Per RECIST 1.1 | 63.6 (40.7 to 82.8) | 44.4 (21.5 to 69.2) |
DOR was defined as the duration of time between the date of the first documented response (CR or PR) and the date of first documented progression or death due to any cause
| Months | Safety Run-In (Investigational Arm 1): NIS793+SoC | Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC |
|---|---|---|
| (Safety run-in Part) Duration of Response (DOR) by Investigator Assessment Per RECIST 1.1 | 9.4 (NA to NA) | NA (NA to NA) |
TTR was defined as the duration of time between the date of enrollment and the date of the first documented response of either CR or PR
| Months | Safety Run-In (Investigational Arm 1): NIS793+SoC | Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC |
|---|---|---|
| (Safety run-in Part) Time to Response (TTR) by Investigator Assessment Per RECIST 1.1 | NA (NA to NA) | NA (NA to NA) |
OS was defined as the time from the date of enrollment to the date of death due to any cause
| Months | Safety Run-In (Investigational Arm 1): NIS793+SoC | Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC |
|---|---|---|
| (Safety run-in Part) Overall Survival (OS) | 10.2 (5.8 to 20.8) | 11.0 (6.2 to 15.7) |
Blood samples were collected at indicated time-points for analysis of Cmax of NIS793 and tislelizumab.
| ng/mL | Safety Run-In (Investigational Arm 1): NIS793+SoC | Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC |
|---|---|---|
| NIS793: Cycle 1 Day 1 | 556000 ± 161000 | 663000 ± NA |
| NIS793: Cycle 3 Day 1 | 967000 ± 285000 | 1130000 ± NA |
| tislelizumab: Cycle 1 Day 1 | — | 71800 ± 10300 |
| tislelizumab: Cycle 3 Day 1 | — | 90300 ± 11100 |
Blood samples were collected at indicated time-points for analysis of Ctrough of NIS793 and tislelizumab
| ng/mL | Safety Run-In (Investigational Arm 1): NIS793+SoC | Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC |
|---|---|---|
| NIS793: Cycle 1 Day 15 | 164000 ± 59800 | 173000 ± 18700 |
| NIS793: Cycle 3 Day 1 | 406000 ± 178000 | 284000 ± 136000 |
| NIS793: Cycle 3 Day 15 | 439000 ± 165000 | 273000 ± 12700 |
| NIS793: Cycle 6 Day 1 | 699000 ± 324000 | — |
| tislelizumab: Cycle 1 Day 15 | — | 28600 ± 40300 |
| tislelizumab: Cycle 3 Day 1 | — | 21500 ± 8710 |
| tislelizumab: Cycle 3 Day 15 | — | 23600 ± 3700 |
| tislelizumab: Cycle 6 Day 1 | — | 48800 ± 30300 |
Prevalence of NIS793 and Tislelizumab Antidrug antibodies (ADA) at baseline was defined as the proportion of participants who had an ADA positive result at baseline
| Participants | Safety Run-In (Investigational Arm 1): NIS793+SoC (FOLFIRI and mFOLFOX6) | Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI and mFOLFOX6) |
|---|---|---|
| NIS793: ADA-positive (i.e. ADA prevalence) | 0 | 0 |
| Tislelizumab: ADA-positive (i.e. ADA prevalence) | 0 | 2 |
Incidence of NIS793 and Tislelizumab Antidrug antibodies (ADA) on treatment was defined as the proportion of participants who were treatment-induced ADA positive (post-baseline ADA positive with an ADA-negative sample at baseline) and treatment-boosted ADA positive (post-baseline ADA positive with a titer that was at least the fold titer change greater than the ADA-positive baseline titer)
| Participants | Safety Run-In (Investigational Arm 1): NIS793+SoC (FOLFIRI and mFOLFOX6) | Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI and mFOLFOX6) |
|---|---|---|
| NIS793: Treatment-induced ADA-positive | 0 | 0 |
| NIS793: Treatment-boosted ADA-positive | 0 | 0 |
| Tislelizumab: Treatment-induced ADA-positive | 0 | 2 |
| Tislelizumab: Treatment-boosted ADA-positive | 0 | 0 |
The percentage of participants who experienced AEs and SAEs, including changes in laboratory parameters, vital signs, body weight, and cardiac assessments
| Participants | Expansion (Investigational Arm 1): NIS793+SoC (FOLFIRI) | Expansion (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI) | Expansion (Control Arm): SoC (FOLFIRI) | Expansion (Investigational Arm 1): NIS793+SoC (mFOLFOX6) | Expansion (Control Arm): SoC (mFOLFOX6) |
|---|---|---|---|---|---|
| Adverse Events (AEs) | 65 | 26 | 45 | 14 | 7 |
| Serious Adverse Events (SAEs) | 32 | 9 | 14 | 6 | 3 |
| Fatal SAEs | 0 | 0 | 0 | 0 | 0 |
| AEs leading to discontinuation | 19 | 5 | 9 | 5 | 3 |
| AEs leading to dose adjustment/interruption | 47 | 17 | 34 | 9 | 5 |
| AEs requiring additional therapy | 60 | 26 | 39 | 14 | 6 |
Tolerability was measured by the percentage of subjects who had dose adjustments (interruptions) of the investigational drug (e.g., NIS793, NIS793 + tislelizumab)
| Participants | Expansion (Investigational Arm 1): NIS793+SoC (FOLFIRI) | Expansion (Investigational Arm 1): NIS793+SoC (mFOLFOX6) | Expansion (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI) |
|---|---|---|---|
| NIS793: Participants with at least one dose reduction | 1 | 0 | 0 |
| NIS793: Participants with at least one dose interruption | 40 | 8 | 10 |
| Tislelizumab: Participants with at least one dose reduction | 0 | 0 | 0 |
| Tislelizumab: Participants with at least one dose interruption | 0 | 0 | 6 |
Tolerability was measured by the dose intensity of the investigational drug (e.g., NIS793, NIS793 + Tislelizumab). Dose intensity was computed as the ratio of the actual cumulative dose received to the actual duration of exposure.
| mg/cycle | Expansion (Investigational Arm 1): NIS793+SoC (FOLFIRI) | Expansion (Investigational Arm 1): NIS793+SoC (mFOLFOX6) | Expansion (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI) |
|---|---|---|---|
| NIS793 | 3865.2 ± 591.35 | 3786.2 ± 437.93 | 3982.1 ± 393.43 |
| Tislelizumab | — | — | 290.8 ± 19.39 |
ORR was defined as the proportion of participants with a best overall response (BOR) of complete response (CR) or partial response (PR), as per investigator assessment and according to RECIST 1.1
| Percentage of Responders | Expansion (Investigational Arm 1): NIS793+SoC | Expansion (Investigational Arm 2): NIS793+TISLE+SoC | Expansion (Control Arm): SoC |
|---|---|---|---|
| (Expansion Part) Overall Response Rate (ORR) by Investigator Assessment Per RECIST 1.1 | 8.8 (3.6 to 17.2) | 13.8 (3.9 to 31.7) | 15.1 (6.7 to 27.6) |
DCR was defined as the proportion of participants with a best overall response (BOR) of complete response (CR), partial response (PR), or stable disease (SD), as per investigator assessment and according to RECIST 1.1
| Percentage of Responders | Expansion (Investigational Arm 1): NIS793+SoC | Expansion (Investigational Arm 2): NIS793+TISLE+SoC | Expansion (Control Arm): SoC |
|---|---|---|---|
| (Expansion Part) Disease Control Rate (DCR) by Investigator Assessment Per RECIST 1.1 | 66.3 (54.8 to 76.4) | 65.5 (45.7 to 82.1) | 79.2 (65.9 to 89.2) |
DOR was defined as the duration of time between the date of the first documented response (CR or PR) and the date of first documented progression or death due to any cause
| Months | Expansion (Investigational Arm 1): NIS793+SoC | Expansion (Investigational Arm 2): NIS793+TISLE+SoC | Expansion (Control Arm): SoC |
|---|---|---|---|
| (Expansion Part) Duration of Response (DOR) by Investigator Assessment Per RECIST 1.1 | 9.5 (4.0 to NA) | NA (NA to NA) | 11.1 (3.8 to NA) |
TTR was defined as the duration of time between the date of enrollment and the date of first documented response of either CR or PR
| Months | Expansion (Investigational Arm 1): NIS793+SoC | Expansion (Investigational Arm 2): NIS793+TISLE+SoC | Expansion (Control Arm): SoC (FOLFIRI) |
|---|---|---|---|
| (Expansion Part) Time to Response (TTR) by Investigator Assessment Per RECIST 1.1 | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
OS was defined as the time from the date of enrollment to the date of death due to any cause
| Months | Expansion (Investigational Arm 1): NIS793+SoC | Expansion (Investigational Arm 2): NIS793+TISLE+SoC | Expansion (Control Arm): SoC |
|---|---|---|---|
| (Expansion Part) Overall Survival (OS) | 12.8 (8.0 to 14.2) | 10.9 (6.1 to NA) | NA (11.6 to NA) |
Blood samples were collected at indicated time-points for analysis of Cmax of NIS793 and tislelizumab
| ng/mL | Expansion (Investigational Arm 1): NIS793 + SoC | Expansion (Investigational Arm 2): NIS793 + Tislelizumab + SoC |
|---|---|---|
| NIS793: Cycle 1 Day 1 | 598000 ± 178000 | 694000 ± 478000 |
| NIS793: Cycle 3 Day 1 | 904000 ± 301000 | 871000 ± 315000 |
| tislelizumab: Cycle 1 Day 1 | — | 93400 ± NA |
Blood samples were collected at indicated time-points for analysis of Ctrough of NIS793 and tislelizumab
| ng/mL | Expansion (Investigational Arm 1): NIS793 + SoC | Expansion (Investigational Arm 2): NIS793 + Tislelizumab + SoC |
|---|---|---|
| NIS793: Cycle 1 Day 15 | 189000 ± 56200 | 181000 ± 50000 |
| NIS793: Cycle 3 Day 1 | 371000 ± 1116000 | 391000 ± 100000 |
| NIS793: Cycle 3 Day 15 | 394000 ± 121000 | 342000 ± 186000 |
| NIS793: Cycle 6 Day 1 | 365000 ± 180000 | — |
| tislelizumab: Cycle 2 Day 1 | — | 25400 ± 19600 |
| tislelizumab: Cycle 3 Day 1 | — | 29400 ± 12700 |
| tislelizumab: Cycle 4 Day 1 | — | 39400 ± 17100 |
Prevalence of NIS793 and Tislelizumab Antidrug antibodies (ADA) at baseline was defined as the proportion of participants who had an ADA positive result at baseline
| Participants | Expansion (Investigational Arm 1): NIS793 + SoC | Expansion (Investigational Arm 2): NIS793 + Tislelizumab + SoC |
|---|---|---|
| NIS793: ADA-positive (i.e. ADA prevalence) | 0 | 0 |
| Tislelizumab: ADA-positive (i.e. ADA prevalence) | 0 | 1 |
Incidence of NIS793 and Tislelizumab Antidrug antibodies (ADA) on treatment was defined as the proportion of participants who were treatment-induced ADA positive (post-baseline ADA positive with an ADA-negative sample at baseline) and treatment-boosted ADA positive (post-baseline ADA positive with a titer that was at least the fold titer change greater than the ADA-positive baseline titer)
| Participants | Expansion (Investigational Arm 1): NIS793 + SoC | Expansion (Investigational Arm 2): NIS793 + Tislelizumab + SoC |
|---|---|---|
| NIS793: Treatment-induced ADA-positive | 0 | 0 |
| NIS793: Treatment-boosted ADA-positive | 0 | 0 |
| Tislelizumab: Treatment-induced ADA-positive | 0 | 0 |
| Tislelizumab: Treatment-boosted ADA-positive | 0 | 0 |
Collected over Adverse Events (AEs) were recorded from the first dose of study medication through 30 days after the last dose of Standard of Care, with assessments spanning approximately 38 months. The Safety Run-in phase averaged 162.5 days (about 5.4 months), while the Expansion phase averaged 221.3 days (about 7.4 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Safety Run-In (Investigational Arm 1): NIS793+SoC(FOLFIRI) | 8/13 (61.5%) | 6/13 (46.2%) | 0/13 (0%) |
| Safety Run-In (Investigational Arm 1): NIS793+SoC (mFOLFOX6) | 5/9 (55.6%) | 6/9 (66.7%) | 0/9 (0%) |
| Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI) | 8/10 (80%) | 6/10 (60%) | 0/10 (0%) |
| Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (mFOLFOX6) | 2/8 (25%) | 5/8 (62.5%) | 0/8 (0%) |
| Expansion (Investigational Arm 1): NIS793+SoC (FOLFIRI) | 33/65 (50.8%) | 32/65 (49.2%) | 0/65 (0%) |
| Expansion (Investigational Arm 1): NIS793+SoC (mFOLFOX6) | 9/15 (60%) | 6/15 (40%) | 0/15 (0%) |
| Expansion (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI) | 12/29 (41.4%) | 9/29 (31%) | 0/29 (0%) |
| Expansion (Control Arm): SoC (FOLFIRI) | 13/46 (28.3%) | 14/46 (30.4%) | 0/46 (0%) |
| Expansion (Control Arm): SoC (mFOLFOX6) | 3/7 (42.9%) | 3/7 (42.9%) | 0/7 (0%) |
| Event | Safety Run-In (Investigational Arm 1): NIS793+SoC(FOLFIRI) | Safety Run-In (Investigational Arm 1): NIS793+SoC (mFOLFOX6) | Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI) | Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (mFOLFOX6) | Expansion (Investigational Arm 1): NIS793+SoC (FOLFIRI) | Expansion (Investigational Arm 1): NIS793+SoC (mFOLFOX6) | Expansion (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI) | Expansion (Control Arm): SoC (FOLFIRI) | Expansion (Control Arm): SoC (mFOLFOX6) |
|---|---|---|---|---|---|---|---|---|---|
| PyrexiaGeneral disorders | 0/13 | 0/9 | 2/10 | 0/8 | 0/65 | 1/15 | 1/29 | 4/46 | 1/7 |
| Myocardial infarctionCardiac disorders | 0/13 | 0/9 | 0/10 | 0/8 | 0/65 | 0/15 | 0/29 | 0/46 | 1/7 |
| Infusion related reactionInjury, poisoning and procedural complications | 0/13 | 0/9 | 0/10 | 0/8 | 0/65 | 0/15 | 0/29 | 0/46 | 1/7 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/13 | 0/9 | 0/10 | 0/8 | 1/65 | 2/15 | 0/29 | 1/46 | 0/7 |
| AnaemiaBlood and lymphatic system disorders | 0/13 | 0/9 | 0/10 | 1/8 | 3/65 | 0/15 | 1/29 | 0/46 | 0/7 |
| Abdominal painGastrointestinal disorders | 0/13 | 0/9 | 0/10 | 1/8 | 1/65 | 0/15 | 0/29 | 1/46 | 0/7 |
| DiarrhoeaGastrointestinal disorders | 0/13 | 0/9 | 1/10 | 1/8 | 4/65 | 0/15 | 2/29 | 2/46 | 0/7 |
| VomitingGastrointestinal disorders | 0/13 | 0/9 | 0/10 | 1/8 | 1/65 | 0/15 | 0/29 | 0/46 | 0/7 |
| Mucosal inflammationGeneral disorders | 0/13 | 0/9 | 0/10 | 1/8 | 0/65 | 0/15 | 0/29 | 0/46 | 0/7 |
| CellulitisInfections and infestations | 0/13 | 0/9 | 0/10 | 1/8 | 0/65 | 0/15 | 0/29 | 0/46 | 0/7 |
| Age, Categorical(Participants) | Safety Run-In (Investigational Arm 1): NIS793+SoC (FOLFIRI) | Safety Run-In (Investigational Arm 1): NIS793+SoC (mFOLFOX6) | Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI) | Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (mFOLFOX6) | Expansion (Investigational Arm 1): NIS793+SoC (FOLFIRI) | Expansion (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI) | Expansion (Control Arm): SoC (FOLFIRI) | Expansion (Investigational Arm 1): NIS793+SoC (mFOLFOX6) | Expansion (Control Arm): SoC (mFOLFOX6) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 11 | 6 | 6 | 5 | 46 | 24 | 36 | 11 | 4 | 149 |
| >=65 years | 2 | 3 | 4 | 3 | 21 | 5 | 10 | 2 | 3 | 53 |
| Sex: Female, Male(Participants) | Safety Run-In (Investigational Arm 1): NIS793+SoC (FOLFIRI) | Safety Run-In (Investigational Arm 1): NIS793+SoC (mFOLFOX6) | Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI) | Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (mFOLFOX6) | Expansion (Investigational Arm 1): NIS793+SoC (FOLFIRI) | Expansion (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI) | Expansion (Control Arm): SoC (FOLFIRI) | Expansion (Investigational Arm 1): NIS793+SoC (mFOLFOX6) | Expansion (Control Arm): SoC (mFOLFOX6) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 11 | 3 | 2 | 2 | 29 | 11 | 18 | 8 | 2 | 86 |
| Male | 2 | 6 | 8 | 6 | 38 | 18 | 28 | 5 | 5 | 116 |
| Race (NIH/OMB)(Participants) | Safety Run-In (Investigational Arm 1): NIS793+SoC (FOLFIRI) | Safety Run-In (Investigational Arm 1): NIS793+SoC (mFOLFOX6) | Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI) | Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (mFOLFOX6) | Expansion (Investigational Arm 1): NIS793+SoC (FOLFIRI) | Expansion (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI) | Expansion (Control Arm): SoC (FOLFIRI) | Expansion (Investigational Arm 1): NIS793+SoC (mFOLFOX6) | Expansion (Control Arm): SoC (mFOLFOX6) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 2 | 2 | 1 | 1 | 15 | 5 | 10 | 4 | 0 | 40 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 5 |
| White | 10 | 7 | 9 | 7 | 50 | 20 | 34 | 9 | 7 | 153 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Nov 2021 to primary completion in Jan 2025, 38 months.
Results were first posted in Nov 2026, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nisevokitug